Connect with us

Spread & Containment

Bathurst Metals

OverviewNorthern Canada remains one of the largest untouched mining regions in the world, leaving plenty of room for future exploration, production, and growth. Today, the mineral resource industry is the greatest private sector contributor to Nunavut’s..

Published

on




Overview


Northern Canada remains one of the largest untouched mining regions in the world, leaving plenty of room for future exploration, production, and growth. Today, the mineral resource industry is the greatest private sector contributor to Nunavut’s economy. Mineral production alone contributed over C$1.3 billion economic activity in 2019, which created ample employment opportunities and significant benefits for business growth.

Nunavut, Canada, has an extensive history of exploration and mining and is well-known for its high-grade geology. Considered a tier 1 mining jurisdiction, Nunavut has seen a significant surge in mining activity throughout the last decade. Although COVID-19 dealt a setback in mineral exploration in 2020 — with just C$70.7 million spent out of a projected C$115 million — in 2021, exploration spending was back on track and peaked at C$123.2 million. With all land claims settled, permits in place for exploration and conventional environmental laws, there’s no geopolitical risk with Nunavut’s proactive and responsive local government.

Bathurst Metals Corp. (TSXV:BMV, OTC:BMVVF) is a mineral exploration company operating in Nunavut with their portfolio of highly prospective projects which include the Turner Lake,TED property, Gela Lake, McGregor Lake, Speers Lake and McAvoy Lake. All properties have had surface work and/or drilling completed, all of which demonstrated excellent results. The company is led by an accomplished board and management team, bringing world-class credentials and decades of experience to the team.


Bathurst Metals


“Bathurst Metals has a very strong portfolio of 100 percent owned properties in Nunavut with experienced staff familiar with working in these areas,” said Bathurst Metals Director Greg Bronson P. Geo.

All of Bathurst Metals’ projects are in close proximity to other established mining companies, including Agnico Eagle Mines’ (TSX:ASM, NYSE:AEM) Meadowbank and Meliadine gold mines, and recently purchased TMAC Resources’ Hope Bay gold mine Sabina Gold & Silver Corp.(TSX:SBB) Back River Gold Project and Baffinland Iron Mines’ (TSX:BIM) Mary River iron ore mine.

Bathurst Metals is proud to present a compelling investment opportunity in the gold and metals exploration sectors and believes the historical work on their project portfolio shows excellent potential for gold, silver, copper, nickel, cobalt, platinum and palladium deposits. Because Bathurst Metals owns all the properties, there’s no geopolitical risk and no native land issues, making it equally enticing to investors.


Bathurst Metals Project

Company Highlights


  • Bathurst Metals is focused on exploring, acquiring and developing mineral properties throughout Nunavut, Canada.
  • All of Bathurst Metals’ properties are 100 percent owned. They currently have six projects in their portfolio: Turner Lake, TED, McGregor Lake, Gela Lake, McAvoy Lake and Speers Lake.
  • Bathurst Metals is led by an accomplished board and management team, bringing world class credentials and key geologists on their various projects.
  • The Turner Lake Project is known for containing significant gold concentrations along a Fe/Mg Tholeiite contact. There is visible gold in almost all historic diamond drill holes crossing this contact.
  • The company’s TED project is located south-west of the Turner Lake project and expands across an eight (8) kilometer strike length.


Key Projects


Turner Lake


Bathurst Turner Lake


Bathurst Metals’ Turner Lake project is located 14 kilometers from tidewater in western Nunavut. According to Hardy Forzley, Chairman and CEO of Bathurst Metals, “The Turner Lake project is known to contain significant gold concentrations along an iron/magnesium tholeiite contact with visible gold noted in almost every diamond drill hole crossing the structure.”

Historical diamond drilling and surface sampling on the property were done by Chevron Minerals between 1986-1989 and Northrock Resources between 2008-2009. Diamond drilling results from Chevron Minerals included: 28.00 g/tonne gold /4.75 meters, 12.86g/tonne gold / 8.87 meters, 15.20 g/tonne gold / 4.00 meters , 10.0 0 g/tonne gold / 4.00 meters. Northrock Resources diamond drilling results included: 13.20 g/tonne gold /13.00 meters, 22.54 g/tonne gold /12.00 meters and 16.20 g/tonne gold /8.50 meters.


TED Property


Ted Property


Bathurst Metals’ TED project is located in western Nunavut, approximately 55 kilometers north-northwest of the Bathurst inlet community on the fault line adjacent south-west of the Turner Lake Project.

The TED project consists of the T4-6 mineral claims staked by Bathurst Metals spanning across their 3,500 hectare property. This property mainly consists of metasediments and conglomerates — key lithologies found at other successful goldmines like Sabina, Meadowbank, and Meliadine, also located in western Nunavut.

Bathurst Metals announced high grade gold assay results from 18 rock grab samples collected during their 2021 summer sampling program from the TED Gold Zone of the Turner Lake project. Six (6) of the (18) samples assayed had values greater than 20 g/tonne gold. One sample is especially notable assayed at a value of 106 g/tonne gold. Historical grab samples were recorded up to 138.2g/t, 70.3g/t, 68.9g/t, 42.9g/t and 33.8g/t gold.

McGregor Lake

Bathurst Metals’ McGregor Lake project is a palladium, platinum and gold property in Western Nunavut, approximately 300 kilometers south of Kugluktuk and about 100 kilometers east of the Northwest Territory border.

The McGregor Lake project consists of 11 mineral claims that cover roughly 13,125 hectares across the exposed Layered Muskox Ultramafic Intrusive (LMUI). Airborne surveys have shown that this LMUI may be the largest layered ultramafic complex ever seen, with exposed surfaces over 80 kilometers along the strike. Geophysical, geochemical and geological mapping, along with historical diamond drilling, have indicated a minimum of two sulfide pulses in the area.

Speers Lake

The Speers Lake project is located adjacent to the north side of the McGregor Lake Project, which is approximately 300 kilometers south of Kugluktuk and about 100 kilometers east of the Northwest Territory border.

The Speers Lake area was first explored in the 1950s but wasn’t looked at again until 30 years later in the 1980s. Scattered diamond drill testing was once again completed between 1999 and 2007 and geophysical, geochemical and geological mapping took place. At least two sulfide pulses were found along the LMUI, containing high concentrations of nickel and copper along with gold, platinum

Gela Lake


Gela Lake

The Gela Lake project is located close to tidewater in the Kitikmeot region of western Nunavut, in the same region as the Turner and McAvoy projects.

This project has the potential for a large tonnage deposit of cobalt, nickel and copper. There have been high-grade copper mineralization in quartz veins that are affiliated with cobalt blooms occurring with a monzogabbro intrusive. This intrusive found along the regional Bathurst Inlet Fault, is known to outcrop over a two (2) kilometer strike length.

McAvoy Lake

Bathurst Metals’ McAvoy Lake project has a four (4) kilometer stretch of gold mineralization formed along the north-south Bathurst Inlet Fault. The project is located close to tidewater in the Kitikmeot region of western Nunavut in proximity to the Turner and Gela Lakes projects.

Grab and channel samples in the 1980s yielded 64.0 grams/tonne gold, and there are veins of quartz and felsic dyking with pyrite, trace amounts of chalcopyrite and arsenopyrite that vary in size from 0.2 to 2.5 meters wide. Besides saw marks from the channel samples, there is no evidence of any previous exploratory sampling.

Management Team



Harold (Hardy) Forzley - Chairman and Chief Executive Officer

Harold Forzley is the founding director and CEO of the company. He has over 30 years experience in managing and financing public and private companies. He’s been involved in many public companies at various stages of exploration and development, with several that resulted in the sale and development of major mines. Hardy’s primary focus is on project management, strategic planning and financing activities. Mr. Forzley has a B Comm. degree from Simon Fraser University and a CPA.CA designation. - Chief Financial Officer


Lorne McLeod Warner, P.Geo. - President

Lorne Warner is a registered professional geologist in B.C, NWT and Nunavut with over 30 years’ experience in underground and open pit mining mineral exploration. His experience includes working for senior mining companies, Noranda Exploration and Placer Dome Inc, as well as being Vice President of several junior mining companies. Lorne’s team was first to conduct exploration at Detour Lake after closure by Placer Dome. They discovered the western extension of the Detour Lake Gold Deposit, that’s now in production in Ontario. They also discovered the Falea North Zone – Uranium, Silver, Copper Deposit and the Fatou Main Gold Deposit, both in Mali, West Africa. His career started in British Columbia, but he has now worked throughout the Americas, Africa, Asia and Australia. Lorne is currently a director, President and CEO of Tarachi Gold Corp. in Mexico and is working as a director of Indigo Exploration Inc. in West Africa. Lorne McLeod Warner graduated from the University of Alberta in 1986 with a BSc. in Geology.


David McAdam - Chief Financial Officer

Mr. McAdam is a Senior Executive with over 30 years of finance and operations experience in large and small capitalization companies, David has extensive expertise in fund raising (over $350 million in equity and debt), financial operations and planning, due diligence, investor relations (TSX.V and JSE), risk management and regulatory compliance. David has been the Chief Financial Officer of several public and private companies across various industry sectors including a number of public and private mining companies He is currently on the Board of Interra Copper Corp, where he chairs the Audit Committee. David has a Bachelor of Commerce degree from the University of British Columbia


Greg Bronson, P.Geo. - Director

Greg Bronson is a Professional Geologist with 30 years exploration and development experience in mining and the oil and gas industry. He brings excellent skills to manage the complex technical issues of mineral exploration. He has worked in Canada for the major mining company called Noranda Exploration (now Xstrata) and for many junior resource companies, including Rockgate Capital Corp (now Denison Mines), Sentinel Resources Corp, and others.

Mr. Bronson is President of Benjamin Hill Mining, a junior mining company with interests and active projects in Sonora, Mexico. Mr. Bronson sits on the board of Sentinel Resources Corp. and oil and gas junior Avanti Energy Inc.


Stephen Millen - Director

Stephen Millen's career has spanned over four decades, covering communications, marketing, sales and general management in the resource exploration and electronic security business. Stephen’s experience ranges from entrepreneurial start-ups to senior management with a multinational corporation. He has served as an officer and director of several public companies focusing on corporate communications and business development.


Dr. Guowei Zhang, PhD., P Geo., - Advisor

Dr. Zhang has over 30 years experience as a consulting geologist, well recognized for his specialized work in Structural Geology. He received his Ph.D. from McGill University in 1994 and has been working extensively throughout Canada, the United States, Asia and Africa. Dr. Zhang is a Fellow of the Geological Association of Canada.


Peter R. B. Armstrong - Advisor

Peter Armstrong is the Founder of the Armstrong Group. The Armstrong Group of companies includes the globally recognized Rocky Mountaineer luxury tourism train company founded by Mr. Armstrong himself in 1989; Alder Bay Equity Partners, which holds private equity positions in steel fabricating, 3rd party logistics, specialized glass distribution and agricultural equipment businesses; and Invictus Properties, a real estate holding company with a wide range of assets.

Mr. Armstrong has held many board positions in public, private and not-for-profit entities, and has extensive knowledge of corporate and philanthropic board governance. Mr. Armstrong received his Executive MBA from Harvard Business School.


Ken Hallat - Advisor

Ken Hallat acquired Savolite Soap in 1967 and, through acquisitions, grew it into one of the largest privately owned cleaning chemical manufacturers in North America. He co-founded PlanetClean and expanded it into a 15 chain distribution group that was sold to Bunzl, a UK based public company.

Mr. Hallat is a past director of SunRype Products, founding director and shareholder of Sleeman Breweries and his family company, Novas Capital Corp. has invested in a wide range of business assets. He has served on the boards of many public, private and not-for-profit companies and foundations and has an extensive working knowledge of corporate and philanthropic board governance. He received his MBA (Hons.) from the University of British Columbia.

Read More

Continue Reading

Government

40,000 National Guard Troops Face Unemployment As Vaccine Deadline Imminent

40,000 National Guard Troops Face Unemployment As Vaccine Deadline Imminent

Up to 40,000 Army National Guard troops – around 13% of the force…

Published

on

40,000 National Guard Troops Face Unemployment As Vaccine Deadline Imminent

Up to 40,000 Army National Guard troops - around 13% of the force - could be fired for not getting the mandated COVID-19 vaccine (which has limited efficacy against Omicron, doesn't stop transmission, has been linked to elevated heart problems, and has been mandated for a healthy demographic that rarely dies of the disease).

Michigan Army National Guard Sgt. Mark Abbott administers a COVID-19 vaccine

Guard soldiers have until Thursday to get the jab, according to the Associated Press, which notes that between 20% and 30% of Guard soldiers in six states remain unvaccinated.

"We’re going to give every soldier every opportunity to get vaccinated and continue their military career. Every soldier that is pending an exemption, we will continue to support them through their process," Lt. Gen. Jon Jensen, director of the Army National Guard, told AP. "We’re not giving up on anybody until the separation paperwork is signed and completed. There’s still time."

Last year, Defense Secretary Lloyd Austin ordered all service members to get the vaccine, with different branches maintaining different deadlines for the jab. The Army National Guard was given the maximum amount of time, largely because its roughly 330,000 soldiers are scattered throughout the country, including remote locations.

The Army Guard’s vaccine percentage is the lowest among the U.S. military — with all the active-duty Army, Navy, Air Force and Marine Corps at 97% or greater and the Air Guard at about 94%. The Army reported Friday that 90% of Army Reserve forces were partially or completely vaccinated.

The Pentagon has said that after June 30, Guard members won’t be paid by the federal government when they are activated on federal status, which includes their monthly drill weekends and their two-week annual training period. Guard troops mobilized on federal status and assigned to the southern border or on COVID-19 missions in various states also would have to be vaccinated or they would not be allowed to participate or be paid. -AP

Complicating matters is a rule that Guard soldiers deployed on state active duty may not require a vaccination, depending on state-level mandates. 

According to the report, at least seven governors have asked Austin to reconsider, or drop, the vaccine mandate for National Guard members - with some having filed or joined lawsuits to that end.

Austin, apparently following his own special brand of science, told them to pound sand, saying that Covid-19 "takes our service members out of the fight, temporarily or permanently, and jeopardizes our ability to meet mission requirements," adding that troops will either need to get vaccinated or lose their Guard status.

"When you’re looking at, 40,000 soldiers that potentially are in that unvaccinated category, absolutely there’s readiness implications on that and concerns associated with that," said Jenson, adding "That's a significant chunk." 

AP reports that around 85% of Army Guard soldiers are fully vaccinated, while 87% are at least partially vaccinated.

Tyler Durden Sun, 06/26/2022 - 18:00

Read More

Continue Reading

Government

CDC Confirmed Post-Vaxx Death From Blood-Clotting Two Weeks Before Alerting Public: Emails

CDC Confirmed Post-Vaxx Death From Blood-Clotting Two Weeks Before Alerting Public: Emails

Authored by Zachary Stieber via The Epoch Times…

Published

on

CDC Confirmed Post-Vaxx Death From Blood-Clotting Two Weeks Before Alerting Public: Emails

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

The Centers for Disease Control and Prevention (CDC) confirmed in late 2021 that a person died from blood clotting after receiving a COVID-19 vaccine that had been linked with an increased risk of blood clotting, but did not alert the public for two weeks, newly obtained emails show.

A general view of the Centers for Disease Control headquarters in Atlanta, Ga., on April 23, 2020. (Tami Chappell/AFP via Getty Images)

Dr. Tom Shimabukuro, a CDC official, told colleagues at the CDC and the Food and Drug Administration (FDA) on Dec. 2, 2021, “We have confirmed a 9th TTS death following Janssen vaccination,” according to emails obtained by The Epoch Times through a Freedom of Information Act request.

TTS refers to thrombosis with thrombocytopenia syndrome, a condition that features low platelet levels combined with blood clots.

Officials had recommended a nationwide pause on the administration of the vaccine, produced by Johnson & Johnson (J&J) subsidiary Janssen, in April 2021 after six women experienced TTS after J&J vaccination and three died. But they lifted the pause after determining the vaccine remained safe and effective.

The condition was not discussed much in the ensuing months, despite the CDC later reporting that five additional deaths occurred before Aug. 31, 2021. Shimabukuro gave a single update, in mid-October 2021, saying five total deaths had been reported.

That was until December 2021. Twelve days after Shimabukuro alerted colleagues of the ninth death, the FDA urged healthcare workers not to administer the vaccine to people with certain conditions because of the TTS risk. Two days after that, Dr. Isaac See, another CDC official, informed the public during a meeting that nine deaths had occurred post-vaccination.

It’s unclear when the CDC learned of the sixth, seventh, and eighth deaths.

The CDC takes reports made to the Vaccine Adverse Event Reporting System and attempts to confirm the reports, including post-vaccination deaths. A higher number of post-vaccination TTS deaths have been reported to the system than the number the CDC has verified.

One day after Shimabukuro confirmed the ninth death, his message was forwarded by Dr. Amanda Cohn, another CDC official, to CDC Director Dr. Rochelle Walensky.

“See below, information on a 9th completely tragic death from TTS,” Cohn wrote.

Many thanks for letting us know … any tragic case,” Walensky responded.

The emails were partially redacted; one was fully redacted.

Read more here...

Tyler Durden Sun, 06/26/2022 - 15:30

Read More

Continue Reading

Spread & Containment

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) Breaking Out as Biotech Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is moving steadily northbound with power after the Company reported Brilacidin, its defensin-mimetic drug…

Published

on

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is moving steadily northbound with power after the Company reported Brilacidin, its defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron and Delta variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with (NIH) and (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma and Alpha variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin).  

Emerging SARS-CoV-2 variants, and increasingly their sub-variants, contain immunity-evading mutations. These mutations alter key parts of the SARS-CoV-2 spike protein that attach to human cells, making the virus more transmissible and potentially more virulent. Unlike other antivirals, such as monoclonal antibodies, and most vaccines, Brilacidin has been shown not to target the Spike S1 and Spike RBD regions of SARS-CoV-2, acting instead through dual-acting neutralizing and blocking antiviral properties, able to target virus and host. These antiviral traits support Brilacidin’s ability to maintain its anti-coronavirus activity and suggest Brilacidin would be less subject to resistance. Taken together, the results from NIH/NIAID testing of Brilacidin are supportive of previously completed research and give the Company confidence in the compound’s antiviral potential. The Company remains active in pursuing additional government-based funding opportunities, as well as licensing partnerships, to advance Brilacidin in the highly attractive area of developing novel broad-spectrum medicines for treating viral diseases. Microcapdaily has been reporting on IPIX for a long time and we were there when the stock (then trading as CTIX) made a legendary run skyrocketing to $4.93 per share. 

Subscribe To Our 100% Free Penny Stock Newsletter!

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is a clinical stage pharmaceutical company developing innovative therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The Company owns the rights to Brilacidin, its lead drug in a new class of compounds called defensin-mimetics, and Kevetrin (thioureidobutyronitrile), its anti-cancer compound. Brilacidin is being studied by the Company, as well as other independent researchers, as a potential broad-spectrum antiviral therapeutic for the treatment of viruses including the novel coronavirus (SARS-CoV-2), which is responsible for COVID-19. 

Brilacidin is Innovation Pharma’s lead drug candidate in its Host Defense Protein (HDP)-mimetic franchise. Brilacidin has been granted Fast Track designation by the FDA and currently is being evaluated in a randomized, placebo-controlled Phase 2 clinical trial in hospitalized COVID-19 patients (see NCT04784897). Two independent Machine Learning (AI) studies also identified Brilacidin as one of the most promising inhibitors of SARS-CoV-2, the virus responsible for COVID-19, based on Brilacidin’s molecular properties. Modeled after HDPs, the “front-line” of defense in the body’s innate immune system, it is a synthetic, non-peptidic small molecule that kills pathogens swiftly, significantly reducing the likelihood of drug resistance developing. Just as importantly, Brilacidin functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing. 

Kevetrin is a small molecule that has demonstrated the potential of becoming a breakthrough cancer treatment by inducing activation of p53, a protein frequently referred to as the “Guardian of the Genome” due to its critical role in controlling cell mutations. In most cancers, regardless of origin, type, and location, the p53 pathway becomes inactivated (dysfunctional), thus preventing the body from performing its natural anti-tumor functions. The TP53 gene is the most studied gene of all time. Conducted at the Dana-Farber Cancer Institute and at Beth Israel Deaconess Medical Center, a Phase 1 clinical trial evaluating Kevetrin in treating Advanced Solid Tumors has been successfully completed, with patients showing good toleration and encouraging signs of potential therapeutic response. The Company has concluded its open-label, dose-escalation Phase 2a trial of Kevetrin in Platinum-Resistant/Refractory Ovarian Cancer. Highly encouraging preliminary data from the first patients treated in the trial showed modulation of the p53 protein in response to administration of Kevetrin. With a promising bioavailability profile, and to leverage its short half-life (the drug exits the body in approximately 8 to 10 hours), efforts are underway to develop Kevetrin as an oral anti-cancer agent (tablet or capsule) that can be administered daily, potentially even multiple times per day. The FDA has awarded Kevetrin Orphan Drug status for Ovarian Cancer, Pancreatic Cancer, and Retinoblastoma, qualifying it for developmental incentives and an extra 7 years of market exclusivity upon drug approval. The FDA also has granted Kevetrin Rare Pediatric Disease designation for childhood Retinoblastoma. 

Microcapdaily has been covering IPIX for years starting with CTIX back in 2015 reporting on the stocks legendary run to $4.93 per share. We stated on CTIX back in the day: “As anyone in the industry knows, regulating the p53 pathway has long been the holy grail of cancer research and big pharma has spent hundreds of millions of dollars researching ways to achieve this with no success thus far. It seems Kevetrin(TM) has accomplished this; extensive preclinical research on Kevetrin shows the re-activation of p53 across a wide spectrum of cancer lines including colon, lung, breast and pancreatic cancers. The market potential for Kevetrin in treating drug-resistant cancers is worth $5 billion a year. Other cancers could easily represent an additional $5 billion annually, he adds.”

IPIX has established a valuable intellectual property portfolio: 

To Find out the inside Scoop on IPIX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

IPIX

On June 23 IPIX reported Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron (B.1.1.529) and Delta (B.1.617.2) variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma (P.1) and Alpha (B.1.1.7) variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin). Identifying COVID-19 countermeasures with novel mechanisms of action is vital. SARS-CoV-2 continues to evolve at an accelerated pace, raising questions as to what the dominant variant (or sub-variant) may be this fall and winter, when infections often spike — and if today’s COVID-19 vaccines and therapeutics can maintain their effectiveness. 

Emerging SARS-CoV-2 variants, and increasingly their sub-variants, contain immunity-evading mutations. These mutations alter key parts of the SARS-CoV-2 spike protein that attach to human cells, making the virus more transmissible and potentially more virulent. Unlike other antivirals, such as monoclonal antibodies, and most vaccines, Brilacidin has been shown not to target the Spike S1 and Spike RBD regions of SARS-CoV-2, acting instead through dual-acting neutralizing and blocking antiviral properties, able to target virus and host. These antiviral traits support Brilacidin’s ability to maintain its anti-coronavirus activity and suggest Brilacidin would be less subject to resistance. Related, results from new NIH/NIAID in vitro testing of Brilacidin in over 20 acutely infectious viruses, and from the Brilacidin Phase 2 COVID-19 clinical trial, are being prepared for publication. Findings from the Rutgers’ Brilacidin research can be accessed at the link below1 and build on earlier published Brilacidin research conducted by scientists at George Mason University and at University of Arizona and University of California-San Francisco. 

In 2021, the Company completed a Phase 2 clinical trial of Brilacidin (NCT04784897) for treatment of moderate-to-severe COVID-19 patients. While the trial did not meet its primary endpoint in reducing time to sustained recovery through day 29, certain patient subgroups did show treatment benefits of Brilacidin for that primary endpoint. For example, patients treated early from onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p=0.03). To date, only a modicum of success has been demonstrated by any company conducting clinical trials in moderate-to-severe hospitalized cases of COVID-19. A possible reason for this may be owing to frequent changes in the standard of care with patients receiving a cocktail of fluctuating concomitant medications, which complicates the interpretation of the clinical trial data and that of the new drug candidate being evaluated. Clinical observations of COVID-19 patients treated with Brilacidin further lead us to believe that higher and more frequent dosing of Brilacidin may be more appropriate to tackle this complex disease in the hospital setting. 

Taken together, the results from NIH/NIAID testing of Brilacidin are supportive of previously completed research and give the Company confidence in the compound’s antiviral potential. The Company remains active in pursuing additional government-based funding opportunities, as well as licensing partnerships, to advance Brilacidin in the highly attractive area of developing novel broad-spectrum medicines for treating viral diseases. 

For More on IPIX Subscribe Right Now!

Currently trading at an $18 million market valuation IPIX has $8.7 million in the treasury, over $11 million in assets vs. $4.5 million in total liabilities. IPIX is CTIX reincarnated and this stock can move skyrocketing to $4.93 per share back in the day; a run we reported on from the beginning. IPIX is heating up and getting noticed by investors after the Company reported Brilacidin, its defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron and Delta variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with (NIH) and (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma and Alpha variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin). We will be updating on IPIX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with IPIX.

WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?

Disclosure: we hold no position in IPIX either long or short and we have not been compensated for this article.

The post Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) Breaking Out as Biotech Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing first appeared on Micro Cap Daily.

Read More

Continue Reading

Trending